| __timestamp | Soleno Therapeutics, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2917513 | 10811000 |
| Thursday, January 1, 2015 | 7878291 | 33001000 |
| Friday, January 1, 2016 | 8366794 | 64936000 |
| Sunday, January 1, 2017 | 6610381 | 99909000 |
| Monday, January 1, 2018 | 6556000 | 127724000 |
| Tuesday, January 1, 2019 | 6930000 | 161524000 |
| Wednesday, January 1, 2020 | 8758000 | 182933000 |
| Friday, January 1, 2021 | 10806000 | 219982000 |
| Saturday, January 1, 2022 | 9844000 | 278139000 |
| Sunday, January 1, 2023 | 13481000 | 309799000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational expenses is crucial for sustainability and growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Soleno Therapeutics, Inc. over a decade, from 2014 to 2023.
Ultragenyx has seen a staggering increase in SG&A expenses, growing nearly 2,800% from 2014 to 2023. This reflects their aggressive expansion strategy, as they invest heavily in marketing and administrative capabilities to support their innovative therapies.
In contrast, Soleno Therapeutics has maintained a more conservative approach, with SG&A expenses increasing by approximately 360% over the same period. This suggests a focus on cost efficiency while navigating the challenges of drug development.
Understanding these trends provides valuable insights into each company's operational strategies and their potential impact on future growth.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: AbbVie Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared